Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

BACKGROUND: The functional activity of the organic cation transporter 1 (OCT-1) protein (OCT-1 activity) is an excellent predictor of molecular response and progression-free survival in patients with newly diagnosed chronic phase chronic myeloid leukemia treated with imatinib as front-line therapy....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: White, Deborah L., Radich, Jerald, Soverini, Simona, Saunders, Verity A, Frede, Amity K., Dang, Phuong, Cilloni, Daniela, Lin, Peter, Mongay, Lidia, Woodman, Richard, Manley, Paul, Slader, Cassandra, Kim, Dong Wook, Pane, Fabrizio, Martinelli, Giovanni, Saglio, Giuseppe, Hughes, Timothy P.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2012
Assuntos:
Original Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3366658/
https://ncbi.nlm.nih.gov/pubmed/22207690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.056457
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados